PharmaDrug Advances with PD-001 Clinical Trials

Pharmadrug Inc. (TSE:PHRX) has released an update.

PharmaDrug’s subsidiary Sairiyo Therapeutics has wrapped up the clinical and regulatory preparations necessary for a Phase 1 study in Australia, targeting the use of PD-001, a reformulated version of cepharanthine, for infectious diseases and cancer treatment. The company is poised to submit for ethical approval and looks forward to benefitting from Australia’s R&D tax incentives, with an eye on future FDA trials in the United States. PD-001 offers improved oral bioavailability over traditional cepharanthine, potentially enhancing therapeutic outcomes for patients.

For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.